Abstract:Patient‐reported outcomes regarding symptom burden may provide valuable information in addition to physician assessment. Systematic collection of patient‐reported outcomes may be an important metric to identify unmet needs and improve quality of patient care. To understand common symptoms of patients seen in radiation oncology clinic, we examined the prospectively collected modified Edmonton Symptom Assessment Scale (ESAS‐r) data to explore symptom clusters. Our clinic established use of a modified Edmonton Sy… Show more
“…Symptoms were assessed through the patients' self-report on an expanded Edmonton Symptom Assessment Scale-Revised (ESAS-r-css), [7][8][9] a well-validated, brief measure of common symptoms in patients with cancer. Item level scores were documented in the EHR at the initial SCM clinic visit.…”
Background: The use of cannabis by cancer patients has become increasingly common. With expanding access to medical cannabis, unsanctioned cannabis use is likely to increase. Despite this, the extent to which patients seeking specialized palliative or supportive care for cancer-related symptoms are actively using cannabis has not been well established. Objective: We sought to determine the extent to which patients seeking specialized symptom management were using cannabis and to compare the severity of cancer-related symptoms between users and nonusers. Methods: We conducted a retrospective review of objectively measured tetrahydrocannabinol (THC) and subjectively reported cannabis use, its demographic and clinical correlates, and patient-reported symptoms in 816 cancer patients in active treatment referred to a supportive/palliative care outpatient clinic for specialized symptom management between January 2014 and May 2017. Results: Nearly one-fifth (19.12%) tested positive for THC on urine drug testing. Users were younger, more likely to be men, single, and to have a history of cigarette smoking. Users also were likely to be more recently diagnosed and to have received radiotherapy. Certain moderate-to-severe symptoms, such as lack of appetite, shortness of breath, tiredness, difficulty sleeping, anxiety, and depression, were associated with use after accounting for sociodemographic and clinical differences between cannabis users and nonusers. Conclusions: Findings suggest patients seeking specialized symptom management are self-treating with cannabis, despite the lack of high-quality evidence for its use in palliative care. Unsanctioned use is likely to increase in cancer patients. Accurate information is urgently needed to help manage patient expectations for its use and increase understanding of risks and benefits.
“…Symptoms were assessed through the patients' self-report on an expanded Edmonton Symptom Assessment Scale-Revised (ESAS-r-css), [7][8][9] a well-validated, brief measure of common symptoms in patients with cancer. Item level scores were documented in the EHR at the initial SCM clinic visit.…”
Background: The use of cannabis by cancer patients has become increasingly common. With expanding access to medical cannabis, unsanctioned cannabis use is likely to increase. Despite this, the extent to which patients seeking specialized palliative or supportive care for cancer-related symptoms are actively using cannabis has not been well established. Objective: We sought to determine the extent to which patients seeking specialized symptom management were using cannabis and to compare the severity of cancer-related symptoms between users and nonusers. Methods: We conducted a retrospective review of objectively measured tetrahydrocannabinol (THC) and subjectively reported cannabis use, its demographic and clinical correlates, and patient-reported symptoms in 816 cancer patients in active treatment referred to a supportive/palliative care outpatient clinic for specialized symptom management between January 2014 and May 2017. Results: Nearly one-fifth (19.12%) tested positive for THC on urine drug testing. Users were younger, more likely to be men, single, and to have a history of cigarette smoking. Users also were likely to be more recently diagnosed and to have received radiotherapy. Certain moderate-to-severe symptoms, such as lack of appetite, shortness of breath, tiredness, difficulty sleeping, anxiety, and depression, were associated with use after accounting for sociodemographic and clinical differences between cannabis users and nonusers. Conclusions: Findings suggest patients seeking specialized symptom management are self-treating with cannabis, despite the lack of high-quality evidence for its use in palliative care. Unsanctioned use is likely to increase in cancer patients. Accurate information is urgently needed to help manage patient expectations for its use and increase understanding of risks and benefits.
“…Interestingly, no respondents indicated use of the ESAS for distress screening, although its large-scale use in the clinic-based collection of patient-reported outcomes in a manner similar to distress screening has been documented by at least one MI. 11,12 The relatively widespread use of the Patient Health Questionnaire and Generalized Anxiety Disorder Assessment scales among respondents seems indicative of the persistent focus on psychological indicators of distress. Their use may also reflect cancer centers' efforts to adhere to ASCO's recommendations for the screening, assessment, and treatment of adult patients with cancer who have symptoms of depression and anxiety.…”
The first NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Distress Management were published in 1999. Since then, a number of other organizations have advocated for distress screening. Previous surveys of distress screening showed modest progress in implementation of the NCCN Guidelines for Distress Management by NCCN Member Institutions (MIs); this review examined whether further progress has been made. Representatives appointed to the NCCN Distress Management Panel or their designee were asked to complete an online survey in the summer of 2018. The survey was developed based on similar surveys performed in 2005 and 2012 and a survey of psychosocial staffing conducted in NCCN MIs in 2012. New items solicited details about triaging, rescreening, formal screening protocols, and tracking of distressed patients. The survey was completed by representatives from 23 of 27 NCCN MIs (85%). Among the responding institutions, 20 (87%) currently conduct routine screening for distress and 3 are piloting routine screening. All respondents reported use of a self-report measure to screen for distress, with the Distress Thermometer most often used. A total of 70% of respondents rescreen patients for distress and 83% reported having a formal distress screening protocol in place. Once triaged, 65% of institutions who routinely screen for distress track clinical contacts and referrals; 70% track rates of adherence to screening protocols. Findings suggest wide acceptance and implementation of the NCCN Guidelines. Most respondents reported the existence of a formal distress screening protocol, with routine tracking of clinical contacts and referrals and rates of protocol adherence. Clinical experience and the American College of Surgeons Commission on Cancer accreditation standard for cancer centers appear to have resulted in greater adoption and implementation of the guidelines, but considerable opportunities for improvement remain.
“…Unfortunately, this approach fails to account for the possibly strong correlation in symptom burden measures taken from the same patient. 8 Moreover, the relationship between patient-level predictors and symptom burden may be nonlinear and complex, making it difficult to explicitly capture using traditional regression techniques.…”
Section: Methodological Backgroundmentioning
confidence: 99%
“…When several symptoms for each patient are being considered, each symptom is often examined separately meaning that an independent regression model is developed for each symptom. Unfortunately, this approach fails to account for the possibly strong correlation in symptom burden measures taken from the same patient 8 . Moreover, the relationship between patient‐level predictors and symptom burden may be nonlinear and complex, making it difficult to explicitly capture using traditional regression techniques.…”
INTRODUCTION 1.1 | Clinical background Patients diagnosed with cancer may experience multiple symptoms, often co-occurring throughout their disease trajectory. Commonly reported symptoms include pain, fatigue, anxiety, lack of appetite, and lack of well-being 1-4 ; and a majority of patients experience both severe fatigue and lack of well-being in the initial months after diagnosis. 5 The prevalence and intensity of these symptoms varies by patient characteristics. Younger age, female sex, higher comorbidity burden, and lower income
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.